Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology
- PMID: 17493029
- DOI: 10.1111/j.1365-2788.2006.00902.x
Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology
Abstract
Background: The clinical and neuropathological features associated with dementia in Down's syndrome (DS) are not well established. Aims To examine clinico-pathological correlations and the incidence of cognitive decline in a cohort of adults with DS.
Method: A total of 92 hospitalized persons with DS were followed up from 1985 to December 2000. At outset, 87 participants were dementia-free, with a median age of 38 years. Assessments included the Prudhoe Cognitive Function Test (PCFT) and the Adaptive Behavior Scale (ABS), to measure cognitive and behavioural deterioration. Dementia was diagnosed from case records and caregivers' reports.
Results: Eighteen (21%) patients developed dementia during follow-up, with a median age of onset 55.5 years (range 45-74). The PCFT demonstrated cognitive decline among those with a less severe intellectual disability (mild and moderate) but not among the profoundly disabled people (severe and profound). Clinical dementia was associated with neuropathological features of Alzheimer's disease, and correlated with neocortical neurofibrillary tangle densities. At the age of 60 years and above, a little more than 50% of patients still alive had clinical evidence of dementia.
Conclusions: Clinical dementia associated with measurable cognitive and functional decline is frequent in people with DS after middle age, and can be readily diagnosed among less severely intellectually disabled persons using measures of cognitive function such as the PCFT and behavioural scales such as the ABS. In the more profoundly disabled people, the diagnosis of dementia is facilitated by the use of behavioural and neurological criteria. In this study, the largest prospective DS series including neuropathology on deceased patients, the density of neurofibrillary tangles related more closely to the dementia of DS than senile plaques. In people with DS surviving to middle and old age, the development of dementia of Alzheimer type is frequent but not inevitable, and some people with DS reach old age without clinical features of dementia.
Similar articles
-
Dementia and mortality in persons with Down's syndrome.J Intellect Disabil Res. 2006 Oct;50(Pt 10):768-77. doi: 10.1111/j.1365-2788.2006.00842.x. J Intellect Disabil Res. 2006. PMID: 16961706 Review.
-
A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline.Brain. 2010 Apr;133(Pt 4):1163-72. doi: 10.1093/brain/awq048. Brain. 2010. PMID: 20375138
-
[Dementia following bipolar disorder].Encephale. 2008 Dec;34(6):606-10. doi: 10.1016/j.encep.2007.12.007. Epub 2008 Apr 2. Encephale. 2008. PMID: 19081458 French.
-
The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome.J Intellect Disabil Res. 2004 Sep;48(Pt 6):611-20. doi: 10.1111/j.1365-2788.2004.00630.x. J Intellect Disabil Res. 2004. PMID: 15312062
-
Pathological correlates of cognitive decline in Alzheimer's disease.Panminerva Med. 2007 Dec;49(4):191-5. Panminerva Med. 2007. PMID: 18091671 Review.
Cited by
-
Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.Acta Neuropathol Commun. 2022 Jan 4;10(1):2. doi: 10.1186/s40478-021-01300-9. Acta Neuropathol Commun. 2022. PMID: 34983655 Free PMC article.
-
Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.CNS Drugs. 2020 Aug;34(8):785-794. doi: 10.1007/s40263-020-00740-6. CNS Drugs. 2020. PMID: 32506291 Free PMC article. Review.
-
Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients.PLoS One. 2019 Apr 5;14(4):e0211575. doi: 10.1371/journal.pone.0211575. eCollection 2019. PLoS One. 2019. PMID: 30951523 Free PMC article.
-
Epigenomics of Alzheimer's disease.Transl Res. 2015 Jan;165(1):200-20. doi: 10.1016/j.trsl.2014.05.006. Epub 2014 May 16. Transl Res. 2015. PMID: 24905038 Free PMC article. Review.
-
Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.Int Rev Res Dev Disabil. 2022;62:227-263. doi: 10.1016/bs.irrdd.2022.05.006. Epub 2022 Jul 21. Int Rev Res Dev Disabil. 2022. PMID: 37396708 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical